Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002008
- Locations
- ๐บ๐ธ
UCLA CARE Ctr, Los Angeles, California, United States
๐บ๐ธBeth Israel Deaconess - West Campus, Boston, Massachusetts, United States
Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Schering-Plough
- Registration Number
- NCT00002070
- Locations
- ๐บ๐ธ
Children's Hosp of San Francisco, San Francisco, California, United States
๐บ๐ธPacific Presbyterian, San Francisco, California, United States
๐บ๐ธDr Douglas Dieterich, New York, New York, United States
A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002009
- Locations
- ๐บ๐ธ
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
๐บ๐ธUCLA CARE Ctr, Los Angeles, California, United States
A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002007
- Locations
- ๐บ๐ธ
Natl Cancer Institute, Bethesda, Maryland, United States
A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002263
- Locations
- ๐บ๐ธ
Natl Cancer Institute / HIV / AIDS Malignancy Branch, Bethesda, Maryland, United States
A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 24
- Registration Number
- NCT00000681
- Locations
- ๐บ๐ธ
UCLA CARE Center CRS, Los Angeles, California, United States
๐บ๐ธPitt CRS, Pittsburgh, Pennsylvania, United States
๐บ๐ธSUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 18
- Registration Number
- NCT00000694
- Locations
- ๐บ๐ธ
Mem Sloan - Kettering Cancer Ctr, New York, New York, United States
Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 60
- Registration Number
- NCT00000711
- Locations
- ๐บ๐ธ
SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 250
- Registration Number
- NCT00000658
- Locations
- ๐บ๐ธ
UCLA CARE Center CRS, Los Angeles, California, United States
๐บ๐ธUSC CRS, Los Angeles, California, United States
๐บ๐ธUcsf Aids Crs, San Francisco, California, United States
The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 108
- Registration Number
- NCT00000850
- Locations
- ๐บ๐ธ
UCLA CARE Ctr, Los Angeles, California, United States
๐บ๐ธMarin County Specialty Clinic, San Rafael, California, United States
๐บ๐ธRush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.